Status:
TERMINATED
Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to treat patients with retinal vein occlusion with standard of care anti-vascular endothelial growth factor therapy and to correlate levels of vascular endothelial growth ...
Detailed Description
Ten patients, 5 with branch retinal vein occlusion and 5 with central retinal vein occlusion, will receive stand of care anti-vascular endothelial growth factor over the course of 52 weeks while under...
Eligibility Criteria
Inclusion
- Willingness and ability to provide written informed consent.
- Diagnosis of Retinal Vein Occlusion with macular edema and central foveal thickness of greater than or equal to 300 microns confirmed by intravenous fluorescein angiography and Optical Coherence Tomography
- Visual Acuity between 20/25 and 5/200
Exclusion
- Bilateral Retinal Vein Occlusion
- Vision worse than 5/200 in study eye
- History of myocardial infarction, ischemia, or cerebrovascular accident within 6 weeks of screening
- Concurrent Proliferative Diabetic Retinopathy and/or Maculopathy
- Concurrent Exudative Age-related Macular Degeneration
- Concurrent optic neuropathy with the presence of an afferent pupillary defect
- Previous vitrectomy in the study eye
- Currently pregnant or planning to become pregnant during the duration of the study. Women currently breastfeeding are also excluded.
- Previous treatment for retinal vein occlusion in the study eye
- Any current medical condition which, in the opinion of the investigator is considered to be uncontrolled
- History of allergy or hypersensitivity to study treatment, fluorescein, or any study procedure and treatment related ingredients (e.g. topical anesthetics, betadine, etc.)
Key Trial Info
Start Date :
October 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2023
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04707625
Start Date
October 6 2021
End Date
December 18 2023
Last Update
February 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Health Sciences
Winston-Salem, North Carolina, United States, 27157